Immune cells for severe brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immune therapy using special T cells (a kind of white blood cell) given directly into the brain tumor area. It's for patients with a severe brain tumor that hasn't improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a severe (Grade 4) brain tumor that is in a critical area.
- Regular treatments like surgery, radiation, or chemotherapy haven't worked or caused bad side effects.
- You are 4 years old or older.
- You are able to care for yourself and do most daily activities.
- Your blood counts, liver, kidney, heart, and other organ functions are good enough.
- You are willing to have a small device (Ommaya capsule) placed in your brain to deliver the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (QH104) for people with an aggressive brain tumor called high-grade glioma that has come back or worsened after standard treatment. The therapy targets a specific protein (B7-H3) on tumor cells to try to fight the cancer.
This trial offers a personalized vaccine (DCVax-L) made from your own tumor cells to patients with glioblastoma (a type of brain cancer) who were not able to join a previous study. The vaccine aims to help your immune system fight the cancer.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests a new treatment that combines a specially designed virus to attack tumor cells with an immunotherapy drug to help the immune system fight the cancer. It is for people whose high-grade glioma (a type of brain tumor) has come back after standard treatment.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
This trial tests an experimental immune cell therapy for a type of brain tumor called malignant meningioma that has come back after standard treatment. The goal is to see if these special immune cells can help control the tumor.
Hear when a new GBM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.